Betta Pharmaceuticals Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beida Pharmaceutical Co., Ltd. was established in 2003 and headquartered in Hangzhou, Zhejiang. It is a high-tech pharmaceutical enterprise founded by a high-level talent team of overseas returnees, with independent intellectual property innovation drug research and development as the core, integrating research and development, production, and market sales. On November 7, 2016, Beida Pharmaceutical was listed on the Shenzhen Stock Exchange under the stock code 300558.SZ. The company independently developed China's first small molecule targeted anticancer drug - Ecetinib hydrochloride (trade name: Kemena), which was approved for launch in June 2011. Since its listing, more than 300000 lung cancer patients have taken it, winning the China Patent Gold Award, the China Industry Award, and the first national first prize for scientific and technological progress in the chemical pharmaceutical industry in China and the business community in Zhejiang Province. In November 2020, the company and its controlling subsidiary Xdiscovery jointly developed a brand new innovative drug with fully independent intellectual property rights - Ensatinib Hydrochloride Capsules (trade name: Beimeina), which was officially approved for marketing, becoming the first domestically produced Class 1 new drug used for the treatment of advanced non-small cell lung cancer with ALK mutation in China, filling the gap in the domestic production of similar drugs. In November 2021, the company collaborated with Beijing Tianguangshi Biotechnology Co., Ltd. to develop bevacizumab injection (trade name: bevacizumab), which was officially approved for marketing. The approved indications are metastatic colorectal cancer and advanced, metastatic, or recurrent non-small cell lung cancer. Bei'anting became the company's first approved macromolecular biological product, the third marketed drug, and also the first bevacizumab biologically similar drug in Zhejiang. For major diseases that seriously affect human health, such as malignant tumors and diabetes, the company continues to increase investment in new drug research and development, with an investment of 680 million yuan in 2019, 740 million yuan in 2020, and 860 million yuan in 2021, accounting for 38.3%. At present, the global multicenter Phase III clinical trial of Ensatinib hydrochloride project is being promoted, and it is expected to become the first lung cancer targeted innovative drug led by a Chinese company to be launched globally. The company actively responds to the national call and has created a biopharmaceutical entrepreneurship and innovation platform - Beida Dream Workshop, to help more scientists achieve their entrepreneurial and innovation dreams. |
| Headquarter | Hangzhou |
| Establish Date | 1/7/2003 |
| Listed Code | 300558.SZ |
| Listed Date | 11/7/2016 |
| Chairman | Ding Lieming. |
| CEO | Ding Lieming. |
| Website | www.bettapharma.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
